Papers associated with grin2b

???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? 1 2 3 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Temporal and spatial transcriptomic dynamics across brain development in Xenopus laevis tadpoles., Ta AC, Huang LC, McKeown CR, Bestman JE, Van Keuren-Jensen K, Cline HT., G3 (Bethesda). January 4, 2022; 12 (1):
	A convergent molecular network underlying autism and congenital heart disease., Rosenthal SB, Willsey HR, Xu Y, Xu Y, Mei Y, Dea J, Wang S, Curtis C, Sempou E, Khokha MK, Chi NC, Willsey AJ, Fisch KM, Ideker T., Cell Syst. November 17, 2021; 12 (11): 1094-1107.e6.
	Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy., Kellner S, Abbasi A, Carmi I, Heinrich R, Garin-Shkolnik T, Hershkovitz T, Giladi M, Haitin Y, Johannesen KM, Steensbjerre Møller R, Berlin S., Elife. July 2, 2021; 10
	Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders., Tang W, Liu D, Traynelis SF, Yuan H., Neuropharmacology. October 15, 2020; 177 108247.
	Subunit-specific effects of poricoic acid A on NMDA receptors., Lee J, Kim C, Yeom HD, Nguyen KVA, Eom S, Lee S, Jung JH, Lee JH, Kim SH, Kim IK, Lee JH, Lee JH., Pharmacol Rep. April 1, 2020; 72 (2): 472-480.
	De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases., Li J, Zhang J, Tang W, Mizu RK, Kusumoto H, XiangWei W, Xu Y, Chen W, Amin JB, Hu C, Kannan V, Keller SR, Wilcox WR, Lemke JR, Myers SJ, Swanger SA, Wollmuth LP, Petrovski S, Traynelis SF, Yuan H., Hum Mutat. December 1, 2019; 40 (12): 2393-2413.
	Functional limb muscle innervation prior to cholinergic transmitter specification during early metamorphosis in Xenopus., Lambert FM, Cardoit L, Courty E, Bougerol M, Thoby-Brisson M, Simmers J, Tostivint H, Le Ray D., Elife. May 30, 2018; 7
	An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups., Perszyk R, Katzman BM, Kusumoto H, Kell SA, Epplin MP, Tahirovic YA, Moore RL, Menaldino D, Burger P, Liotta DC, Traynelis SF., Elife. May 24, 2018; 7
	GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors., Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, André VM., Neuropharmacology. September 1, 2017; 123 322-331.
	Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology., Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, Tankovic A, Kusumoto H, Kosobucki GJ, Schulien AJ, Su Z, Pecha J, Bhattacharya S, Petrovski S, Cohen AE, Aizenman E, Traynelis SF, Yuan H., PLoS Genet. January 17, 2017; 13 (1): e1006536.
	Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model., Heusler P, Tourette A, Cussac D., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2015; 388 (5): 509-16.
	From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes., Platt RJ, Curtice KJ, Twede VD, Watkins M, Gruszczyński P, Bulaj G, Horvath MP, Olivera BM., Toxicon. April 1, 2014; 81 67-79.
	GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy., Lemke JR, Hendrickx R, Geider K, Laube B, Schwake M, Harvey RJ, James VM, Pepler A, Steiner I, Hörtnagel K, Neidhardt J, Ruf S, Wolff M, Bartholdi D, Caraballo R, Platzer K, Suls A, De Jonghe P, Biskup S, Weckhuysen S., Ann Neurol. January 1, 2014; 75 (1): 147-54.
	The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism., Kostakis E, Smith C, Jang MK, Martin SC, Richards KG, Russek SJ, Gibbs TT, Farb DH., Mol Pharmacol. August 1, 2013; 84 (2): 261-74.
	Antagonism of NMDA receptors by butanesulfonyl-homospermine guanidine and neuroprotective effects in in vitro and in vivo., Masuko T, Suzuki T, Miyake M, Kusama-Eguchi K, Kizawa Y, Tomono K, Kashiwagi K, Igarashi K, Kusama T., Neurosci Lett. January 11, 2012; 506 (2): 251-5.
	A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons., Kostakis E, Jang MK, Russek SJ, Gibbs TT, Farb DH., J Neurochem. November 1, 2011; 119 (3): 486-96.
	Amyloid β peptide oligomers directly activate NMDA receptors., Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C., Cell Calcium. March 1, 2011; 49 (3): 184-90.
	Soluble factors from IL-1β-stimulated astrocytes activate NR1a/NR2B receptors: implications for HIV-1-induced neurodegeneration., Jing T, Wu L, Borgmann K, Surendran S, Ghorpade A, Liu J, Xiong H., Biochem Biophys Res Commun. November 12, 2010; 402 (2): 241-6.
	Residues at the tip of the pore loop of NR3B-containing NMDA receptors determine Ca2+ permeability and Mg2+ block., Cavara NA, Orth A, Hicking G, Seebohm G, Hollmann M., BMC Neurosci. October 19, 2010; 11 133.
	Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach., Mony L, Triballeau N, Paoletti P, Acher FC, Bertrand HO., Bioorg Med Chem Lett. September 15, 2010; 20 (18): 5552-8.
	Characterization of conantokin Rl-A: molecular phylogeny as structure/function study., Gowd KH, Watkins M, Twede VD, Bulaj GW, Olivera BM., J Pept Sci. August 1, 2010; 16 (8): 375-82.
	Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors., Dravid SM, Burger PB, Prakash A, Geballe MT, Yadav R, Le P, Vellano K, Snyder JP, Traynelis SF., J Neurosci. February 17, 2010; 30 (7): 2741-54.
	Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit., Karakas E, Simorowski N, Furukawa H., EMBO J. December 16, 2009; 28 (24): 3910-20.
	Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors., Masuko T, Namiki R, Nemoto Y, Miyake M, Kizawa Y, Suzuki T, Kashiwagi K, Igarashi K, Kusama T., J Pharmacol Exp Ther. November 1, 2009; 331 (2): 522-30.
	N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse., Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, Lozovaya NA, Jane DE, Monaghan DT., J Pharmacol Exp Ther. November 1, 2009; 331 (2): 618-26.
	Molecular and functional characterization of Xenopus laevis N-methyl-d-aspartate receptors., Schmidt C, Hollmann M., Mol Cell Neurosci. October 1, 2009; 42 (2): 116-27.
	Control of NMDA receptor function by the NR2 subunit amino-terminal domain., Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF., J Neurosci. September 30, 2009; 29 (39): 12045-58.
	Cloning and Phylogenetic Analysis of NMDA Receptor Subunits NR1, NR2A and NR2B in Xenopus laevis Tadpoles., Ewald RC, Cline HT., Front Mol Neurosci. September 11, 2009; 2 4.
	Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors., Mosley CA, Myers SJ, Murray EE, Santangelo R, Tahirovic YA, Kurtkaya N, Mullasseril P, Yuan H, Lyuboslavsky P, Le P, Wilson LJ, Yepes M, Dingledine R, Traynelis SF, Liotta DC., Bioorg Med Chem. September 1, 2009; 17 (17): 6463-80.
	Effects of NR1 splicing on NR1/NR3B-type excitatory glycine receptors., Cavara NA, Orth A, Hollmann M., BMC Neurosci. April 6, 2009; 10 32.
	Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice., Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S, Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek L, Herms J, Van Leuven F., Neurobiol Aging. February 1, 2009; 30 (2): 241-56.
	Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors., Sivaprakasam M, Hansen KB, David O, Nielsen B, Traynelis SF, Clausen RP, Couty F, Bunch L., ChemMedChem. January 1, 2009; 4 (1): 110-7.
	Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors., Mony L, Krzaczkowski L, Leonetti M, Le Goff A, Alarcon K, Neyton J, Bertrand HO, Acher F, Paoletti P., Mol Pharmacol. January 1, 2009; 75 (1): 60-74.
	Molecular determinants of multiple effects of nickel on NMDA receptor channels., Gavazzo P, Guida P, Zanardi I, Marchetti C., Neurotox Res. January 1, 2009; 15 (1): 38-48.
	Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor., Han X, Tomitori H, Mizuno S, Higashi K, Füll C, Fukiwake T, Terui Y, Leewanich P, Nishimura K, Toida T, Williams K, Kashiwagi K, Igarashi K., J Neurochem. December 1, 2008; 107 (6): 1566-77.
	Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies., Ng FM, Geballe MT, Snyder JP, Traynelis SF, Low CM., Mol Brain. October 29, 2008; 1 16.
	Different structural requirements for functional ion pore transplantation suggest different gating mechanisms of NMDA and kainate receptors., Villmann C, Hoffmann J, Werner M, Kott S, Strutz-Seebohm N, Nilsson T, Hollmann M., J Neurochem. October 1, 2008; 107 (2): 453-65.
	Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists., Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, French A, Irier H, Choi WB, Easterling K, Yuan H, Wilson LJ, Kotloski R, McNamara JO, Dingledine R, Liotta DC, Traynelis SF, Snyder JP., J Med Chem. September 25, 2008; 51 (18): 5506-21.
	Differential effects of linear and cyclic polyamines on NMDA receptor activities., Masuko T, Miyake M, Kusama-Eguchi K, Koike T, Kimura E, Kizawa Y, Kashiwagi K, Igarashi K, Kusama T., Neurochem Int. July 1, 2008; 53 (1-2): 38-44.
	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor., Chang HR, Kuo CC., J Med Chem. March 27, 2008; 51 (6): 1534-45.
	Apparent homomeric NR1 currents observed in Xenopus oocytes are caused by an endogenous NR2 subunit., Schmidt C, Hollmann M., J Mol Biol. February 22, 2008; 376 (3): 658-70.
	The activation gate and gating mechanism of the NMDA receptor., Chang HR, Kuo CC., J Neurosci. February 13, 2008; 28 (7): 1546-56.
	Roles of NR2A and NR2B in the development of dendritic arbor morphology in vivo., Ewald RC, Van Keuren-Jensen KR, Aizenman CD, Cline HT., J Neurosci. January 23, 2008; 28 (4): 850-61.
	Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition., Gielen M, Le Goff A, Stroebel D, Johnson JW, Neyton J, Paoletti P., Neuron. January 10, 2008; 57 (1): 80-93.
	The N-terminal domains of both NR1 and NR2 subunits determine allosteric Zn2+ inhibition and glycine affinity of N-methyl-D-aspartate receptors., Madry C, Mesic I, Betz H, Laube B., Mol Pharmacol. December 1, 2007; 72 (6): 1535-44.
	Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors., Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jørgensen L, Clausen RP, Wyllie DJ, Snyder JP, Traynelis SF., Mol Pharmacol. October 1, 2007; 72 (4): 907-20.
	Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block., Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF., J Physiol. May 15, 2007; 581 (Pt 1): 107-28.
	Molecular and functional studies of tilapia (Oreochromis mossambicus) NMDA receptor NR1 subunits., Tzeng DW, Lin MH, Chen BY, Chen YC, Chang YC, Chow WY., Comp Biochem Physiol B Biochem Mol Biol. March 1, 2007; 146 (3): 402-11.
	Cyclophane and acyclic cyclophane: novel channel blockers of N-methyl-D-aspartate receptor., Masuko T, Nagaoka H, Miyake M, Metori K, Kizawa Y, Kashiwagi K, Igarashi K, Kusama T., Neurochem Int. January 1, 2007; 50 (2): 443-9.
	Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission., Frizelle PA, Chen PE, Wyllie DJ., Mol Pharmacol. September 1, 2006; 70 (3): 1022-32.

???pagination.result.page??? 1 2 3 ???pagination.result.next???